Moderna Completes Application To U.S. Food And Drug Administration For Emergency Use Authorization Of Omicron-Targeting Bivalent Covid-19 Booster Vaccine, mRNA-1273.222
mRNA-1273.222 Targets BA.4/BA.5 Strains of Omicron Variant
Pending Authorization, Moderna Ready to Ship Bivalent Booster mRNA-1273.222 in September
Clinical Data Available for Moderna ' s Bivalent COVID-19 Booster Vaccines Have Met All Primary...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials
More News: Clinical Trials | Covid Vaccine | COVID-19 | Emergency Medicine | Food and Drug Administration (FDA) | Pharmaceuticals | Vaccines